{"id":"https://openalex.org/W1628841920","doi":null,"title":"[Interferon beta as a therapy for m\u00faltiple sclerosis]","display_name":"[Interferon beta as a therapy for m\u00faltiple sclerosis]","publication_year":2002,"publication_date":"2002-09-01","ids":{"openalex":"https://openalex.org/W1628841920","mag":"1628841920","pmid":"https://pubmed.ncbi.nlm.nih.gov/12595942"},"language":"es","primary_location":{"id":"pmid:12595942","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12595942","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078495673","display_name":"Fernando Garc\u00eda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189268942","display_name":"Universidad de Alcal\u00e1","ror":"https://ror.org/04pmn0e78","country_code":"ES","type":"education","lineage":["https://openalex.org/I189268942"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"F Zaragoz\u00e1 Garc\u00eda","raw_affiliation_strings":["Departamento de Farmacolog\u00eda. Universidad de Alcal\u00e1. Madrid. Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departamento de Farmacolog\u00eda. Universidad de Alcal\u00e1. Madrid. Spain","institution_ids":["https://openalex.org/I189268942"]}]},{"author_position":"last","author":{"id":null,"display_name":"M Ibarra Lorente","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189268942","display_name":"Universidad de Alcal\u00e1","ror":"https://ror.org/04pmn0e78","country_code":"ES","type":"education","lineage":["https://openalex.org/I189268942"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"M Ibarra Lorente","raw_affiliation_strings":["Departamento de Farmacologia, Universidad de Alcal\u00e1, Madrid,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departamento de Farmacologia, Universidad de Alcal\u00e1, Madrid,","institution_ids":["https://openalex.org/I189268942"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I189268942"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":95},"biblio":{"volume":"26","issue":"5","first_page":"294","last_page":"301"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10137","display_name":"Multiple Sclerosis Research Studies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11668","display_name":"interferon and immune responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/interferon-beta","display_name":"interferon-beta","score":0.9990000128746033},{"id":"https://openalex.org/keywords/multiple-sclerosis","display_name":"multiple sclerosis","score":0.9769999980926514},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.7070000171661377},{"id":"https://openalex.org/keywords/relapse-rate","display_name":"relapse rate","score":0.5099999904632568},{"id":"https://openalex.org/keywords/disease-severity","display_name":"disease severity","score":0.5830000042915344},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.5899999737739563},{"id":"https://openalex.org/keywords/dosing-frequency","display_name":"dosing frequency","score":0.5839999914169312}],"concepts":[{"id":"https://openalex.org/C2780640218","wikidata":"https://www.wikidata.org/wiki/Q8277","display_name":"Multiple sclerosis","level":2,"score":0.7648220062255859},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.757584810256958},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.6337631940841675},{"id":"https://openalex.org/C2776174256","wikidata":"https://www.wikidata.org/wiki/Q830842","display_name":"BETA (programming language)","level":2,"score":0.588760495185852},{"id":"https://openalex.org/C2994247566","wikidata":"https://www.wikidata.org/wiki/Q2450337","display_name":"Interferon beta","level":3,"score":0.5408158898353577},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4187813997268677},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4026029109954834},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3932466506958008},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.16734912991523743},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.16294845938682556},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"pmid:12595942","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12595942","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria","raw_type":"Journal Article"},{"id":"mag:1628841920","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12595942","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W232279843","https://openalex.org/W329292291","https://openalex.org/W1984583580","https://openalex.org/W2010080741","https://openalex.org/W2010432945","https://openalex.org/W2014471226","https://openalex.org/W2015730831","https://openalex.org/W2018080001","https://openalex.org/W2020275618","https://openalex.org/W2036364847","https://openalex.org/W2046354075","https://openalex.org/W2088499363","https://openalex.org/W2093240993","https://openalex.org/W2095666175","https://openalex.org/W2112246282","https://openalex.org/W2123129990","https://openalex.org/W2132228594","https://openalex.org/W2142760583","https://openalex.org/W2169098250","https://openalex.org/W2173824042","https://openalex.org/W2313649737","https://openalex.org/W4252168418"],"related_works":["https://openalex.org/W982415958","https://openalex.org/W2149846873","https://openalex.org/W84334666","https://openalex.org/W1983754834","https://openalex.org/W2048301068","https://openalex.org/W2418075308","https://openalex.org/W2063929317","https://openalex.org/W2015878060","https://openalex.org/W2159343111","https://openalex.org/W4393358588"],"abstract_inverted_index":{"Introduction":[0],"of":[1,17,22,45,57,84],"interferon":[2],"beta":[3],"in":[4,73,100,107],"multiple":[5],"sclerosis":[6],"treatment":[7],"represented":[8],"a":[9,68,114],"great":[10],"advance:":[11],"they":[12],"are":[13],"efficacious":[14],"drugs,":[15],"capable":[16],"reducing":[18],"rate":[19],"and":[20,43,66],"severity":[21],"relapses,":[23],"besides":[24],"improving":[25],"disease":[26],"parameters,":[27],"measured":[28],"by":[29],"MR":[30],"imaging":[31],"techniques.":[32],"However,":[33],"some":[34],"controversy":[35],"has":[36],"been":[37],"raised":[38],"on":[39],"optimal":[40],"doses,":[41],"ways":[42],"frequency":[44,103],"administration.":[46],"In":[47],"this":[48],"article,":[49],"the":[50,55,58,85],"authors":[51],"review":[52],"studies":[53],"about":[54],"efficacy":[56,83,116],"existing":[59],"products,":[60],"as":[61,63],"well":[62],"evidences":[64],"for":[65],"against":[67],"dose-effect":[69],"relationship.":[70],"Although":[71],"differences":[72],"clinical":[74],"trials":[75,110],"make":[76],"comparisons":[77],"difficult,":[78],"available":[79],"data":[80],"indicate":[81],"that":[82,97],"three":[86],"products":[87],"is":[88,92],"quite":[89],"similar.":[90],"There":[91],"no":[93],"basis":[94],"to":[95,113],"believe":[96],"an":[98],"increase":[99],"dose":[101],"or":[102],"over":[104],"those":[105],"used":[106],"phase":[108],"III":[109],"may":[111],"lead":[112],"parallel":[115],"improvement.":[117]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2016,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}